Trobix Bio Raises $3 Million from Chartered Group to Advance Precision Microbiome Oncology Therapeutics
Netanya, Israel, March 30, 2023 – Trobix Bio, a company utilizing CRISPR, phage, and synthetic biology technologies to develop advanced precision microbiome oncology therapeutics, announced today the successful closing of a US $3 million equity investment by Chartered Group, a well-established global private investment group.
The proceeds from this Series A extension round are being utilized to advance the development of Trobix Bio’s products and cutting-edge proprietary platform technology, which addresses the gastrointestinal side effects of oncology treatments and other gastrointestinal diseases impacted by the microbiome.